Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a stronger jolt to the brain beat treatment-resistant depression?

NCT ID NCT02942368

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study tested a noninvasive brain stimulation technique called tDCS in 5 adults with major depression that hadn't improved after at least 3 antidepressant trials. Participants received up to 20 sessions of higher-than-usual electrical current over 4 to 6 weeks. The study was terminated early, so the results are very limited and not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) device
What this could lead to
If it works, this could point toward a non-drug option for people with depression that hasn't responded to multiple medications.
What could go wrong
This was a very small pilot study with only 5 participants and it was terminated early. Higher doses may cause side effects, and the approach is still highly experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

5 people

The number who actually took part.

Started

Apr 2017

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults age 18 to 65 2. History of major depressive disorder with current depressive symptoms, as defined by DSM-IV criteria 3. Baseline score of Hamilton Depression Rating Scale 17-item (HDRS-17) score of 17 or higher 4. Failure of at least 3 prior lifetime antidepressant trials 5. Good command of the English language Exclusion Criteria: 1. Lifetime history of the following, defined by DSM-IV criteria per study physician: 1. Moderate or severe substance use disorder in the past 6 months with the exception of nicotine use disorder 2. Dementia or major neurocognitive disorder 3. Schizophrenia spectrum disorders 4. Autism spectrum disorder 5. Depression which has failed to respond to ECT, with treatment failure as determined by evaluating physician 6. Failure of greater than 6 antidepressant trials in the current depressive episode 2. Current evidence of the following, defined by present symptomology as per study physician: 1. Active psychotic symptoms 2. Bipolar disorder with a current manic, hypomanic, or mixed episode as defined by DSM-IV criteria 3. Depression secondary to a general medical illness 4. Dysphoria better explained by a personality disorder 5. Dysphoria associated with a primary anxiety disorder or PTSD 6. Active suicidal intention (inability to contract for safety) 7. Any change in psychotropic medication within 30 days of the initiation of tDCS 8. History of neurological disorders (e.g., epilepsy) and/or off any treatment medication for a neurological disorder for minimum 3 years (36 months) 9. Any open wounds (e.g., blisters, burns including sun burns, cuts or irritation) under or near the scalp regions where electrodes are placed 10. Metal implants (e.g., Deep Brain Stimulator, Vagus Nerve Stimulator) 11. Any skin disorders (e.g., eczema, severe rashes, sensitive skin, any communicable skin disorder or treatment for a communicable skin disorder in the past 12 months) or other skin defects which compromise the integrity of the skin at or near stimulation locations (where electrodes are placed) 12. Any history of head injury resulting in unconsciousness for more than 5 minutes (e.g., head trauma, brain surgery) 13. Metallic face or scalp tattoos 14. Any chronic headaches or migraines (occurring for consecutive days and are longer than an hour) 15. If a participant has a change in the rate or severity of head pressure, headache, or migraine in the past two weeks, they will also be excluded as per study clinician as we are not aiming to assess the treatment of headache with tDCS 16. Any personal history of seizures. 3. Currently pregnant or lactating, as determined in part from urine pregnancy test at Screening/Baseline appointment and medical history. 4. Any other factor that in the investigators' judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, treatment-resistant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

depressive disorder Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Washington University in Saint Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.